Premium
Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model
Author(s) -
Parada Belmiro,
Reis Flávio,
Figueiredo Arnaldo,
Nunes Pedro,
TeixeiraLemos Edite,
Garrido Patrícia,
Sereno José,
Pinto Rui,
Cunha Maria F.X.,
Neto Paula,
Santos Paulo,
Velada Isabel,
Mota Alfredo,
Teixeira Frederico
Publication year - 2011
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2010.09326.x
Subject(s) - medicine , sirolimus , carcinogen , bladder cancer , urology , carcinogenesis , cancer , urinary system , urinary bladder , urine , gastroenterology , pharmacology , genetics , biology
What’s known on the subject? and What does the study add? Bladder cancer is a very prevalent disease with high recurrence and progression rates despite the best available medical care. This disease could be, in theory, a good model for prevention strategies: the malignant transformation is slow and continuous and there are several drugs that have renal excretion and could be active in the bladder, slowing down or reversing that process. On the other hand, drug concentrations and tumour recurrence could be monitored non‐invasively in the urine. Our study shows that in animal models there are already drugs that show promising results and further investigation in this field could identify agents that could be studied in clinical trials. OBJECTIVE To investigate the anticarcinogenic effects of sirolimus 2 mg/kg/day on a rat model of urinary bladder carcinogenesis induced with N‐butyl‐N(4‐hydroxybutyl)nitrosamine (BBN). MATERIALS AND METHODS Thirty‐six male Wistar rats were divided into four groups: 1, a control group (eight), given tap water only; 2, a sirolimus control group (eight), given 2 mg/kg/day; 3, a carcinogen (BBN) group (12) exposed to 0.05% BBN; 4, a treatment group (sirolimus/BBN; eight) given 2 mg/kg/day + 0.05% BBN. In the tumour‐induction phase, from week 1 to week 8, rats from groups 3 and 4 received BBN ad libitum in drinking water. In the treatment phase, from week 8 to week 20, rats from groups 2 and 4 received sirolimus 2 mg/kg/day by an oesophageal cannula. At week 20 the rats were killed humanely, and the number and size of tumours recorded. The bladders were collected for histological, immunohistochemical and gene expression evaluation. Blood was collected for the determination of several serum proliferative and inflammatory markers. Lipid peroxidation, through serum malondialdehyde (MDA) content, and total antioxidant status (TAS) were also evaluated. RESULTS Sirolimus caused a marked inhibition of bladder tumour growth. When compared with group 3, group 4 had a reduced proportion of rats with tumour (three of eight vs eight of 12), and significantly fewer tumours per rat, with a mean ( sd ) of 1.00 (0.0) vs 1.88 (0.35), and tumour volume per tumour, of 0.30 (0.11) vs 66.1 (48.9) mm 3 , with less aggressive histological changes, i.e. a marked reduction in hyperplasia (four of eight vs 12/12), high‐grade dysplasia (four of eight vs 11/12) and urothelial tumour. Rats in group 4 had no infiltrative bladder cancers and had a lower incidence of high‐grade tumours than rats in group 3. The rats in group 4 had decreased serum levels of transforming growth factor‐β1, higher levels of tumour necrosis factor‐α, and higher levels of serum TAS and a better serum MDA/TAS ratio, a marker of more favourable redox status. Furthermore, the down‐regulation of bladder caspase 3 gene expression and the increased Ki67 immunostaining in group 3 were significantly attenuated in group 4. CONCLUSIONS Sirolimus given as an oral agent, 2 mg/kg/day, significantly inhibited rat bladder carcinogenesis. Sirolimus reduced the number and volume of tumours and induced a less aggressive histological behaviour. This might be due to antiproliferative and antioxidant properties, as well as to the restoration of apoptotic pathways.